查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403517

掌腱膜攣縮症市場至2030年的預測：按疾病類型、治療、診斷、給藥途徑、分銷管道、最終用戶和地區的全球分析

Dupuytren Disease Market Forecasts to 2030 - Global Analysis By Disease Type, Treatment, Diagnosis, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球掌腱膜攣縮症市場規模為 44 億美元，預計到2030年將達到 68.6 億美元，預測期內年複合成長率為 6.6%。

掌腱膜攣縮症，也稱為Dupuytren氏攣縮，是一種影響手部和手指的疾病。其特徵是手掌皮膚下的結締組織增厚和硬化。掌腱膜攣縮症的主要特徵是在手掌上形成結節或腫塊，這些結節或腫塊可能會發展成組織索，將受影響的手指向內拉。

發病率增加

隨著世界人口老化，受掌腱膜攣縮症影響的人數自然也增加，特別是在該病患病率較高的地區。此外，認知的提高和診斷能力的提高有助於更準確、及時地識別掌腱膜攣縮症患者。總體而言，掌腱膜攣縮症的盛行率上升為改善患者照護和新治療方法的市場開拓創造了機會，推動了市場成長。

治療費用高

治療成本是掌腱膜攣縮症市場的一個重要抑制因素，影響了需求。切除術和筋膜切開術等手術介入以及某些藥物治療包括大量費用，包括住院費用、外科醫生費用和術後護理。此外，掌腱膜攣縮症有復發的可能性，需要額外的治療並隨著時間的推移增加患者的總費用。

治療方法的創新

治療方案的技術創新是掌腱膜攣縮症市場的關鍵驅動力，加速了需求。膠原蛋白酶注射劑的引進徹底改變了掌腱膜攣縮症的治療方法。膠原酶是一種分解收縮組織的酶，使受影響的手指伸直。這種非手術方法避免了切口和麻醉的需要，為患者提供了一種侵入性較小的治療選擇。

治療選擇有限

掌腱膜攣縮症在患者之間表現出很大的異質性，其嚴重程度、受影響的手腕關節和治療反應各不相同。這種變異性使得預測治療結果和為每個人選擇最合適的治療變得困難。在某些患者中，儘管經過治療，攣縮的改善可能有限或復發，需要額外的干涉措施或合併治療方法。因此，掌腱膜攣縮症市場的治療選擇有限，對市場成長構成挑戰。

COVID-19 的影響

COVID-19 的爆發對雙相疾病市場產生了重大影響，帶來了影響患者照護和市場動態的挑戰。醫療保健系統優先分配資源來應對這一流行病，擾亂了常規醫療服務並延遲了掌腱膜攣縮症的診斷和治療。此外，疫情期間的供應鏈中斷和製造挑戰影響 Dupuytren 獨特治療方法的可用性和分銷。

預計放射線治療將成為預測期內最大的部門

預計放射線治療領域將佔最大佔有率。放射線治療使用高能量輻射來瞄準和抑制與掌腱膜攣縮症相關的異常組織生長。這種非侵入性治療方法特別適用於疾病晚期的患者，其特徵是出現影響手部功能的攣縮和結節。當多個手指受到影響或手術後復發時尤其有效。

預計注射劑領域在預測期內年複合成長率最高。

預計腸外給藥領域在預測期內將出現良好的成長。在掌腱膜攣縮症中，腸胃外給藥途徑在繞過胃腸道直接向患者體內提供治療性介入方面發揮著非常重要的作用。這種直接方法可確保治療藥物的快速吸收和分佈，在疾病症狀管理中發揮最佳功效。此外，腸胃外途徑最大限度地降低了藥物在胃腸道環境中分解和改變的風險，提高了生物有效性。

佔有率最大的地區

在估計期間，北美佔據了最大的市場佔有率。該地區擁有先進的醫療基礎設施、完善的法律規範以及掌腱膜攣縮症的高盛行率，尤其是在人口老化地區。該地區的醫療保健環境鼓勵採用先進的外科手術、注射治療和非侵入性選擇。此外，該地區的研究機構、製藥公司和醫療保健提供者之間的合作促進新治療方法的開發。

年複合成長率最高的地區：

預計亞太地區在預測期內將實現盈利成長。該地區發生了重大轉變，採用了先進的醫療技術和治療方法掌腱膜攣縮症的方法。不斷增加的研究舉措、區域和國際醫療保健營業單位之間的合作以及不斷發展的醫療保健政策都有助於創新治療方法的開發和採用。該地區的市場開拓進一步受到經濟發展、醫療成本降低以及更注重以患者為中心的護理的推動。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球掌腱膜攣縮症市場：依疾病類型

  • Ⅰ型
  • Ⅱ型
  • Ⅲ型

第6章 全球掌腱膜攣縮症市場：依治療分類

  • 針腱膜切開術
  • 外科手術
  • 酵素注射液
  • 放射治療
  • 類固醇注射
  • 職能治療
  • 其他治療

第7章 全球掌腱膜攣縮症市場：依診斷

  • X光
  • 體檢
  • 其他診斷

第8章 全球掌腱膜攣縮症市場：依給藥途徑

  • 胃腸外
  • 口服
  • 其他給藥途徑

第9章 全球掌腱膜攣縮症市場：按分銷管道

  • 網路藥房
  • 零售藥房
  • 其他分銷管道

第10章 全球掌腱膜攣縮症市場：依最終使用者分類

  • 診所
  • 醫院
  • 學術研究所

第11章 全球掌腱膜攣縮症市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司簡介

  • Pfizer Inc
  • AstraZeneca
  • Endo International plc
  • LEO Pharma A/S
  • Spear Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Bristol-Meyers Squibb Company
  • Fresenius Kabi AG
  • GSK plc
  • Actiza Pharmaceutical Private Limited
  • Nantong Jinghua Pharmaceutical Co., Ltd
  • Novartis AG
  • Bayer AG.
  • Johnson & Johnson Services Ltd.
  • Aurobindo Pharma
Product Code: SMRC24742

According to Stratistics MRC, the Global Dupuytren Disease Market is accounted for $4.40 billion in 2023 and is expected to reach $6.86 billion by 2030 growing at a CAGR of 6.6% during the forecast period. Dupuytren's disease, also known as Dupuytren's contracture, is a medical condition that affects the hands and fingers. It is characterized by the thickening and tightening of the connective tissue beneath the skin in the palm of the hand. The primary feature of Dupuytren's disease is the development of nodules or lumps in the palm, which may progress to form cords of tissue that pull the affected fingers inward.

Market Dynamics:

Driver:

Increasing incidence

As the global population ages, particularly in regions with a higher prevalence of this condition, there is a natural rise in the number of individuals affected by Dupuytren's disease. Moreover, heightened awareness and improved diagnostic capabilities contribute to the more accurate and timely identification of Dupuytren's disease cases. Overall, the escalating incidence of Dupuytren's disease propels market growth by creating opportunities for improved patient care and the development of novel treatment modalities.

Restraint:

High cost of treatment

The cost of treatment serves as a notable restraint in the Dupuytren's disease market, impacting the demand. Surgical interventions, such as fasciectomy or fasciotomy, and certain pharmaceutical treatments involve substantial costs; include hospitalization, surgeon fees, and post-operative care. Moreover, the potential for recurrence in Dupuytren's disease necessitates additional treatments, amplifying the overall cost for patients over time.

Opportunity:

Technological innovations in treatment options

Technological innovations in treatment options are a significant driver in the Dupuytren disease market, accelerating the demand. The introduction of collagenase injections has revolutionized the treatment of Dupuytren disease. Collagenase is an enzyme that can break down the contracted tissue, enabling the straightening of the affected fingers. This non-surgical approach avoids the need for incisions or anaesthesia and provides patients with a less-invasive treatment option.

Threat:

Limited treatment options

Dupuytren disease exhibits significant heterogeneity among patients, with variations in disease severity, affected hand joints, and response to treatments. This variability makes it challenging to predict treatment outcomes and select the most appropriate intervention for each individual. Some patients may experience limited improvement or recurrence of contractures even after undergoing treatment, leading to the need for additional interventions or a combination of treatment approaches. Therefore, the limited treatment options in the dupuytren disease market pose a challenge to market growth.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the Dupuytren disease market, introducing challenges that have influenced both patient care and market dynamics. The healthcare system's prioritization of resources toward managing the pandemic has led to disruptions in routine medical services, delaying the diagnosis and treatment of Dupuytren disease. Additionally, supply chain disruptions and manufacturing challenges during the pandemic have affected the availability and distribution of Dupuytren-specific treatments.

The radiation therapy segment is expected to be the largest during the forecast period

The radiation therapy segment is estimated to hold the largest share. Radiation therapy involves the use of high-energy radiation to target and reduce abnormal tissue growth associated with Dupuytren's disease. This non-invasive treatment modality is particularly considered for individuals with advanced stages of the disease, characterized by contractures and nodules impacting hand function. It is especially beneficial in cases where multiple fingers are affected or when the disease recurs after surgery.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have lucrative growth during the forecast period. In Dupuytren's disease the parenteral route of administration plays a pivotal role in delivering therapeutic interventions directly into the patient's system, bypassing the gastrointestinal tract. This direct approach ensures rapid absorption and distribution of the therapeutic agent, allowing for optimal efficacy in managing the disease's symptoms. Moreover, the parenteral route minimizes the risk of degradation or alteration of the drug in the gastrointestinal environment, enhancing its bioavailability.

Region with largest share:

North America commanded the largest market share during the extrapolated period. The region comprises advanced healthcare infrastructure, a well-established regulatory framework, and a high prevalence of Dupuytren's disease, particularly in the aging population. The region's healthcare landscape encourages the adoption of advanced surgical procedures, injectable treatments, and non-invasive options. Moreover, collaborations between research institutions, pharmaceutical companies, and healthcare providers contribute to the development of novel therapies in this region.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period. In this region, there is a notable shift toward embracing advanced medical technologies and therapies for Dupuytren's disease. Increased research initiatives, collaborations between regional and international healthcare entities, and evolving healthcare policies contribute to the development and adoption of innovative treatment options. The market's growth in this region is further propelled by economic development, improved healthcare affordability, and a heightened focus on patient-centric care.

Key players in the market:

Some of the key players in the Dupuytren Disease Market include Pfizer Inc, AstraZeneca, Endo International plc, LEO Pharma A/S, Spear Pharmaceuticals, Hikma Pharmaceuticals PLC, Bristol-Meyers Squibb Company, Fresenius Kabi AG, GSK plc, Actiza Pharmaceutical Private Limited, Nantong Jinghua Pharmaceutical Co., Ltd, Novartis AG, Bayer AG., Johnson & Johnson Services Ltd. and Aurobindo Pharma.

Key Developments:

In August 2023, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa.

In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles, a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.

Disease Types Covered:

  • Type I
  • Type II
  • Type III

Treatments Covered:

  • Needle Aponeurotomy
  • Surgery
  • Enzyme Injection
  • Radiation Therapy
  • Steroid Shot
  • Occupational Therapy
  • Other Treatments

Diagnosis Covered:

  • X-Ray
  • Physical Examination
  • Other Diagnosis

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Other Route of Administrations

Distribution Channels Covered:

  • Online Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

End Users Covered:

  • Clinics
  • Hospitals
  • Academic & Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dupuytren Disease Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Type I
  • 5.3 Type II
  • 5.4 Type III

6 Global Dupuytren Disease Market, By Treatment

  • 6.1 Introduction
  • 6.2 Needle Aponeurotomy
  • 6.3 Surgery
  • 6.4 Enzyme Injection
  • 6.5 Radiation Therapy
  • 6.6 Steroid Shot
  • 6.7 Occupational Therapy
  • 6.8 Other Treatments

7 Global Dupuytren Disease Market, By Diagnosis

  • 7.1 Introduction
  • 7.2 X-Ray
  • 7.3 Physical Examination
  • 7.4 Other Diagnosis

8 Global Dupuytren Disease Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Parenteral
  • 8.3 Oral
  • 8.4 Other Route Of Administrations

9 Global Dupuytren Disease Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacy
  • 9.3 Retail Pharmacy
  • 9.4 Other Distribution Channels

10 Global Dupuytren Disease Market, By End User

  • 10.1 Introduction
  • 10.2 Clinics
  • 10.3 Hospitals
  • 10.4 Academic & Research Institutes

11 Global Dupuytren Disease Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc
  • 13.2 AstraZeneca
  • 13.3 Endo International plc
  • 13.4 LEO Pharma A/S
  • 13.5 Spear Pharmaceuticals
  • 13.6 Hikma Pharmaceuticals PLC
  • 13.7 Bristol-Meyers Squibb Company
  • 13.8 Fresenius Kabi AG
  • 13.9 GSK plc
  • 13.10 Actiza Pharmaceutical Private Limited
  • 13.11 Nantong Jinghua Pharmaceutical Co., Ltd
  • 13.12 Novartis AG
  • 13.13 Bayer AG.
  • 13.14 Johnson & Johnson Services Ltd.
  • 13.15 Aurobindo Pharma

List of Tables

  • Table 1 Global Dupuytren Disease Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dupuytren Disease Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Dupuytren Disease Market Outlook, By Type I (2021-2030) ($MN)
  • Table 4 Global Dupuytren Disease Market Outlook, By Type II (2021-2030) ($MN)
  • Table 5 Global Dupuytren Disease Market Outlook, By Type III (2021-2030) ($MN)
  • Table 6 Global Dupuytren Disease Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 7 Global Dupuytren Disease Market Outlook, By Needle Aponeurotomy (2021-2030) ($MN)
  • Table 8 Global Dupuytren Disease Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 9 Global Dupuytren Disease Market Outlook, By Enzyme Injection (2021-2030) ($MN)
  • Table 10 Global Dupuytren Disease Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 11 Global Dupuytren Disease Market Outlook, By Steroid Shot (2021-2030) ($MN)
  • Table 12 Global Dupuytren Disease Market Outlook, By Occupational Therapy (2021-2030) ($MN)
  • Table 13 Global Dupuytren Disease Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 14 Global Dupuytren Disease Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 15 Global Dupuytren Disease Market Outlook, By X-Ray (2021-2030) ($MN)
  • Table 16 Global Dupuytren Disease Market Outlook, By Physical Examination (2021-2030) ($MN)
  • Table 17 Global Dupuytren Disease Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 18 Global Dupuytren Disease Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 19 Global Dupuytren Disease Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 20 Global Dupuytren Disease Market Outlook, By Oral (2021-2030) ($MN)
  • Table 21 Global Dupuytren Disease Market Outlook, By Other Route Of Administrations (2021-2030) ($MN)
  • Table 22 Global Dupuytren Disease Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Dupuytren Disease Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 24 Global Dupuytren Disease Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 25 Global Dupuytren Disease Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 26 Global Dupuytren Disease Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Dupuytren Disease Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 28 Global Dupuytren Disease Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Dupuytren Disease Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.